Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
April 25, 2022 07:33 ET
|
Ocugen
MALVERN, Pa., April 25, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and...
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
April 01, 2022 07:37 ET
|
Ocugen
MALVERN, Pa., April 01, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and...
Ocugen, Inc. to Present at the 34th Annual ROTH Conference
March 09, 2022 07:11 ET
|
Ocugen
MALVERN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to...
Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases
August 10, 2020 07:30 ET
|
Ocugen
MALVERN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure...
Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease
July 27, 2020 07:30 ET
|
Ocugen
MALVERN, Pa., July 27, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure...
Foundation Fighting Blindness Celebrates 15th Year of VisionWalk with New Branding
January 09, 2020 14:00 ET
|
Foundation Fighting Blindness
Columbia, MD, Jan. 09, 2020 (GLOBE NEWSWIRE) -- The Foundation Fighting Blindness launches 2020 with a bold, new logo and branding for its signature fundraising event, VisionWalk. VisionWalk...